Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 1.00 |
| ▸ | AKT2 | P31751 | 16/20 | 0.72 |
| ▸ | AKT3 | Q9Y243 | 15/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2174347 | 0.99 | AKT1 (0.98) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL26234267 | 0.89 | AKT1 (0.79) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL31544824 | 0.89 | AKT1 (0.79) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL30574827 | 0.87 | AKT1 (0.80) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL25385750 | 0.87 | AKT1 (0.80) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL13570429 | 0.87 | AKT1 (0.77) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL31455629 | 0.86 | AKT1 (0.81) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL30574929 | 0.85 | AKT1 (0.77) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL25385488 | 0.85 | AKT1 (0.77) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL30802360 | 0.85 | AKT1 (0.74) | AKT1AKT2AKT3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059577-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| EP-2519522-B1 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE INC (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-2519522-B1 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE INC (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8501770-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501770-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501770-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2011082270-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE. INC. (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | MKI67, CDK4, ABL1 | AKT1 2285/4885AKT2 1216/4885AKT3 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.